MNG400
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.293
- PEROXISOME+0.248
- MYOGENESIS+0.150
- MITOTIC_SPINDLE+0.114
- ESTROGEN_RESPONSE_EARLY+0.095
- ESTROGEN_RESPONSE_LATE+0.091
- BILE_ACID_METABOLISM+0.048
- APICAL_JUNCTION+0.047
- CHOLESTEROL_HOMEOSTASIS+0.043
- XENOBIOTIC_METABOLISM+0.041
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.536
- TNFA_SIGNALING_VIA_NFKB-0.488
- ALLOGRAFT_REJECTION-0.476
- IL6_JAK_STAT3_SIGNALING-0.472
- INTERFERON_GAMMA_RESPONSE-0.354
- HYPOXIA-0.343
- MYC_TARGETS_V2-0.342
- WNT_BETA_CATENIN_SIGNALING-0.321
- KRAS_SIGNALING_UP-0.305
- INTERFERON_ALPHA_RESPONSE-0.266
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A5UO-01A-11R-A28M-07 | — | B | 0.840 |
| 2 | SRR1409899 | GTEX | — | 0.815 |
| 3 | SRR8613720 | — | C | 0.814 |
| 4 | SRR1327811 | GTEX | — | 0.802 |
| 5 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.802 |
| 6 | SRR613366 | GTEX | — | 0.801 |
| 7 | SRR29022828 | — | B | 0.800 |
| 8 | aMVAC.P_016_TURBT_S236 | — | — | 0.800 |
| 9 | MDT-AP-2068 | Med | Medulloblastoma | 0.798 |
| 10 | SRR1478768 | GTEX | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.293 | Idelalisib | — uncovered |
| PEROXISOME | 0.248 | Idelalisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.114 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.095 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.091 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.048 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.047 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.043 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.041 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.027 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.024 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.017 | Inavolisib | — uncovered |